Transplanting the Whole Pancreas
Anne L. Peters, MD, CDE: Hi. I am Dr. Anne Peters from the University of Southern California, speaking to you today from the American Diabetes Association (ADA) annual meetings that are being held in Chicago, Illinois. With me is Dr. Michael Rickels, Medical Director of the Pancreatic Islet Cell Transplant Program at the Hospital of the University of Pennsylvania in Philadelphia.
We are going to focus on transplants -- whole organ and islet cell transplants. What do I need to know as a practicing clinician about transplantation in type 1 diabetes?
Michael R. Rickels, MD: Whole organ transplantation involving the pancreas is currently approved as a treatment for type 1 diabetes. Because the whole organ is transplanted and it has a complex blood vessel supply, it has to be transplanted along with part of the small intestine and requires an extensive operation that precludes its use from being widespread. For that reason, the most common indication for a whole pancreas transplant is in conjunction with a kidney transplant in a patient with type 1 diabetes who has diabetic nephropathy and needs a kidney.
Dr. Peters: From the universe of patients who need kidney transplants, would you send for that procedure?
Pediatric Type 1 Diabetes Mellitus
COMMENTARY
Transplant Options for Patients With Type 1 Diabetes
Anne L. Peters, MD, CDE; Michael R. Rickels, MD
DisclosuresJune 28, 2013
Transplanting the Whole Pancreas
Anne L. Peters, MD, CDE: Hi. I am Dr. Anne Peters from the University of Southern California, speaking to you today from the American Diabetes Association (ADA) annual meetings that are being held in Chicago, Illinois. With me is Dr. Michael Rickels, Medical Director of the Pancreatic Islet Cell Transplant Program at the Hospital of the University of Pennsylvania in Philadelphia.
We are going to focus on transplants -- whole organ and islet cell transplants. What do I need to know as a practicing clinician about transplantation in type 1 diabetes?
Michael R. Rickels, MD: Whole organ transplantation involving the pancreas is currently approved as a treatment for type 1 diabetes. Because the whole organ is transplanted and it has a complex blood vessel supply, it has to be transplanted along with part of the small intestine and requires an extensive operation that precludes its use from being widespread. For that reason, the most common indication for a whole pancreas transplant is in conjunction with a kidney transplant in a patient with type 1 diabetes who has diabetic nephropathy and needs a kidney.
Dr. Peters: From the universe of patients who need kidney transplants, would you send for that procedure?
Medscape Diabetes © 2013
Cite this: Transplant Options for Patients With Type 1 Diabetes - Medscape - Jun 28, 2013.
Tables
References
Authors and Disclosures
Authors and Disclosures
Interviewer
Anne L. Peters, MD, CDE
Professor of Clinical Medicine; Director, Clinical Diabetes Programs, Keck School of Medicine, University of Southern California, Los Angeles, California
Disclosure: Anne L. Peters, MD, CDE, has disclosed the following financial relationships:
Served as director, officer, partner, employee, advisor, consultant, or trustee for: (current consultant): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk.
Served as a speaker or member of a speakers bureau for: (current speakers bureau member): Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Novo Nordisk; Takeda Pharmaceuticals North America, Inc.
Served as a consultant or ad hoc speaker/consultant for: AstraZeneca Pharmaceuticals LP; Abbott Laboratories; Boehringer Ingelheim Pharmaceuticals, Inc.; Bristol-Myers Squibb Company; Dexcom; Medtronic MiniMed, Inc.; Merck & Co., Inc.; Roche; sanofi-aventis
Interviewee
Michael R. Rickels, MD
Associate Professor of Medicine, Perelman School of Medicine, University of Pennsylvania; Medical Director, Pancreatic Islet Cell Transplant Program, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania
Disclosure: Michael R. Rickels, MD, has disclosed the following relevant financial relationships:
Serve(d) as a director, officer, partner, employee, advisor, consultant, or trustee for: Longevity Biotech, Inc.
Received income in an amount equal to or greater than $250 from: Longevity Biotech, Inc.